GALAPAGOS NV (GXE.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:GXE - BE0003818359 - Common Stock
GXE.DE Key Statistics, Chart & Performance
The current stock price of GXE.DE is 27.06 EUR.
GXE.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 72.89 | 48.25B | ||
| ARGX.BR | ARGENX SE | 72.78 | 48.17B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.41B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.41B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.39B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.78B | ||
| 5CV.DE | CUREVAC NV | 5.45 | 1.07B | ||
| NANO.PA | NANOBIOTIX | N/A | 837.02M | ||
| PHIL.MI | PHILOGEN SPA | 21.14 | 704.68M | ||
| IVA.PA | INVENTIVA SA | N/A | 699.13M | ||
| 6IV.DE | INVENTIVA SA | N/A | 651.37M | ||
| ALCLS.PA | CELLECTIS | N/A | 444.94M |
Related stock screener links
About GXE.DE
Company Profile
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 558 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Company Info
GALAPAGOS NV
Generaal De Wittelaan L11 A3
MALINES (MECHELEN) ANTWERPEN BE
Employees: 704
Phone: 3215342900
GALAPAGOS NV / GXE.DE FAQ
What does GALAPAGOS NV do?
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 558 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Can you provide the latest stock price for GALAPAGOS NV?
The current stock price of GXE.DE is 27.06 EUR. The price increased by 1.88% in the last trading session.
Does GXE stock pay dividends?
GXE.DE does not pay a dividend.
What is the ChartMill rating of GALAPAGOS NV stock?
GXE.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is GALAPAGOS NV (GXE.DE) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GXE.DE.
What is the next earnings date for GXE stock?
GALAPAGOS NV (GXE.DE) will report earnings on 2026-02-24, after the market close.
GXE.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to GXE.DE.
GXE.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GXE.DE. GXE.DE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GXE.DE Financial Highlights
Over the last trailing twelve months GXE.DE reported a non-GAAP Earnings per Share(EPS) of -6.62. The EPS decreased by -311.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.41% | ||
| ROE | -17.82% | ||
| Debt/Equity | 0 |
GXE.DE Forecast & Estimates
17 analysts have analysed GXE.DE and the average price target is 29.79 EUR. This implies a price increase of 10.09% is expected in the next year compared to the current price of 27.06.
For the next year, analysts expect an EPS growth of -346.2% and a revenue growth -5.39% for GXE.DE